改良格拉斯哥预后评分预测晚期胰腺癌预后的临床价值  

The clinical value of modified Glasgow prognosis score in predicting the prognosis of advanced pancreatic cancer

作　　者：刘怡茜[1] 王健[2] 刘凌翔[1] 束永前[1] Liu Yiqian;Wang Jian;Liu Lingxiang;Shu Yongqian(Department of Oncology,The First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,Jiangsu,China;Department of Oncology,The Fifth People’s Hospital of Changshu,Changshu 215500,Jiangsu,China)

机构地区：[1]南京医科大学第一附属医院肿瘤科,南京210029 [2]常熟市第五人民医院肿瘤内科,江苏常熟215500

出　　处：《肿瘤代谢与营养电子杂志》2020年第4期438-442,共5页Electronic Journal of Metabolism and Nutrition of Cancer

基　　金：国家重点研发计划项目(2017YFC1309201)。

摘　　要：目的探讨改良格拉斯哥预后评分(mGPS)对晚期胰腺癌患者生存的影响,评估其在晚期胰腺癌预后中的潜在临床价值。方法回顾性分析2015年1月至2018年12月南京医科大学第一附属医院肿瘤内科及消化内科治疗的56例晚期胰腺癌的临床资料。分析mGPS及临床特征与患者预后的关系,采用Kaplan-Meier法绘制生存曲线,log-rank进行单因素分析,Cox比例风险模型进行多因素分析影响晚期胰腺癌患者不良预后的预后因素。结果56例患者中男性32例,女性24例,mGPS评分0分、1分、2分患者分别为29例、21例、6例。单因素分析显示年龄≥65岁(P=0.035)、mGPS评分高(P<0.001)、未接受化疗(P<0.001)为影响晚期胰腺癌患者总生存期的危险因素,进一步Cox多因素回归分析提示年龄≥65岁(P=0.021)、mGPS评分为2分(P<0.001)、未接受化疗(P<0.001)为晚期胰腺癌独立预后不良因素。结论mGPS在评估晚期胰腺癌患者的预后中具有重要的临床意义,mGPS评分高提示预后不良。Objective To investigate the effect of modified Glasgow prognosis score(mGPS)on the survival of patients with advanced pancreatic cancer,and to evaluate its potential clinical value in the prognosis of advanced pancreatic cancer.Methods The clinical data of 56 patients with advanced pancreatic cancer treated in the Department of oncology and gastroenterology,the First Affiliated Hospital of Nanjing Medical University from January 2015 to December 2018 were retrospectively analyzed.The relationship between mGPS,clinical features and prognosis was analyzed.Kaplan Meier method was used to draw survival curve,log-rank was used for univariate analysis,and Cox proportional hazard model was used for multivariate analysis to analyze the prognostic factors affecting poor prognosis of patients with advanced pancreatic cancer.Results Among the 56 patients,32 were male and 24 were female.There were 29,21 and 6 patients with mGPS score of 0,1 and 2 respectively.Univariate analysis showed that age≥65 years(P=0.035),high mGPS score(P<0.001)and no chemotherapy(P<0.001)were risk factors for OS in patients with advanced pancreatic cancer.Further multivariate Cox regression analysis showed that age≥65 years(P=0.021),mGPS score of 2(P<0.001)and non chemotherapy(P<0.001)were independent poor prognostic factors of advanced pancreatic cancer.Conclusion mGPS has important clinical significance in evaluating the prognosis of patients with advanced pancreatic cancer.High mGPS score indicates poor prognosis.

关 键 词：胰腺癌 改良格拉斯哥预后评分 治疗结果 预后 

分 类 号：R735.9[医药卫生—肿瘤]